Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb 14;16(6):728-31.
doi: 10.3748/wjg.v16.i6.728.

Endoscopic ultrasound-guided celiac plexus neurolysis using a reverse phase polymer

Affiliations

Endoscopic ultrasound-guided celiac plexus neurolysis using a reverse phase polymer

Keith L Obstein et al. World J Gastroenterol. .

Abstract

Aim: To assess the feasibility of endoscopic ultrasound (EUS)-guided celiac plexus neurolysis (CPN) using a poloxamer.

Methods: In this prospective evaluation, six Yorkshire pigs underwent EUS-guided CPN. Three received an injection of 10 mL of 0.25% Lidocaine plus methylene blue (group 1) and three received an injection of 10 mL of 0.25% Lidocaine plus blue colored poloxamer (PS137-25) (group 2). Necropsy was performed immediately after the animals were sacrificed. The abdominal and pelvic cavities were examined for the presence of methylene blue and the blue colored poloxamer.

Results: EUS-guided CPN was successfully performed in all 6 pigs without immediate complication. Methylene blue was identified throughout the peritoneal and retroperitoneal cavity in group 1. The blue colored poloxamer was found in the retroperitoneal cavity immediately adjacent to the aorta, in the exact location of the celiac plexus in group 2.

Conclusion: EUS-guided CPN using a reverse phase polymer in a non-survival porcine model was technically feasible. The presence of a poloxamer gel at the site of the celiac plexus at necropsy indicates a precise delivery of the neurolytic agent.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Temperature profile of LeGoo-Endo™ (PS137-25) that transits from liquid to gel at body temperature. The viscosity of LeGoo-Endo™ with Lidocaine is slightly higher than LeGoo-Endo™ at body temperature.
Figure 2
Figure 2
Illustration of endoscopic ultrasound (EUS)-guided celiac plexus neurolysis (CPN). Figure from Arcidiacono PG, Rossi M. Celiac Plexus Neurolysis. J Pancreas 2004; 5: 315-321.
Figure 3
Figure 3
EUS-guided injection of Lidocaine plus blue colored poloxamer PS 137-25. The outer margin of the hypoechoic poloxamer is visualized upon injection into the celiac plexus (arrows).
Figure 4
Figure 4
Group 1 (A) and group 2 (B) at necropsy.

Similar articles

Cited by

References

    1. Ventafridda GV, Caraceni AT, Sbanotto AM, Barletta L, De Conno F. Pain treatment in cancer of the pancreas. Eur J Surg Oncol. 1990;16:1–6. - PubMed
    1. Lankisch PG. Natural course of chronic pancreatitis. Pancreatology. 2001;1:3–14. - PubMed
    1. Levy MJ, Topazian MD, Wiersema MJ, Clain JE, Rajan E, Wang KK, de la Mora JG, Gleeson FC, Pearson RK, Pelaez MC, et al. Initial evaluation of the efficacy and safety of endoscopic ultrasound-guided direct Ganglia neurolysis and block. Am J Gastroenterol. 2008;103:98–103. - PubMed
    1. Tran QN, Urayama S, Meyers FJ. Endoscopic ultrasound-guided celiac plexus neurolysis for pancreatic cancer pain: a single-institution experience and review of the literature. J Support Oncol. 2006;4:460–462, 464; discussion 463-464. - PubMed
    1. Michaels AJ, Draganov PV. Endoscopic ultrasonography guided celiac plexus neurolysis and celiac plexus block in the management of pain due to pancreatic cancer and chronic pancreatitis. World J Gastroenterol. 2007;13:3575–3580. - PMC - PubMed

Publication types